User contributions for Alara E. Dagsali

15:2215:22, 28 September 2025 diff hist +1,230 User:AED →Pages Authored/Co-authored/Collaborated current

20:1220:12, 13 May 2025 diff hist +25,945 N Rimegepant Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=rimegepant |aOrAn=an |drugClass=antagonist of the calcitonin gene-related peptide receptor |indicationType=treatment |indication='''Acute Treatment of Migraine''' NURTEC ODT is indicated for the acute treatment of migraine with or without aura in adults. '''Preventive Treatment of Episodic Migraine''' NURTEC ODT is indicated for the preventive treatment of episodic migraine in..." current
10:3010:30, 13 May 2025 diff hist +43,562 N Isatuximab Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=isatuximab |aOrAn=a |drugClass=monoclonal antibody |indicationType=treatment |indication=SARCLISA is indicated: *in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor. *in combination with carfilzomib and dexamethasone, for the t..." current

22:0822:08, 12 May 2025 diff hist +28,979 N Osilodrostat Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=osilodrostat |aOrAn=a |drugClass=inhibits 11beta-hydroxylase |indicationType=treatment |indication=of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative. |adverseReactions=Clinically significant adverse reactions that appear in other sections of the labeling include: *Hypocortisolism *QT Prolongation *Eleva..." current
21:5421:54, 12 May 2025 diff hist +59,391 N Ozanimod Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=ozanimod |aOrAn=a |drugClass=potent S1PR modulator |indicationType=treatment |indication=*relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. *moderately to severely active ulcerative colitis (UC) in adults. |adverseReactions=*Infections *Progressive Multifocal Leu..." current

13:3713:37, 11 May 2025 diff hist +28,699 N Selumetinib Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=selumetinib |aOrAn=a |drugClass=selectively inhibiting MEK1 and MEK2 |indication=KOSELUGO is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). |adverseReactions=The following clinically significant adverse reactions are described elsewhere in the labeling:..." current

14:5614:56, 10 May 2025 diff hist +30,108 N Tucatinib Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=tucatinib |aOrAn=a |drugClass=human epidermal growth factor receptor-2 (HER2) inhibitor |indication='''Metastatic Breast Cancer''' TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior ant..." current

12:4912:49, 9 May 2025 diff hist +31,147 N Pemigatinib Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=pemigatinib |aOrAn=a |drugClass=inhibits FGFR kinase activity |indicationType=treatment |indication='''Cholangiocarcinoma''' PEMAZYRE is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test...." current
12:1912:19, 9 May 2025 diff hist +33,659 N Sacituzumab govitecan Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=sacituzumab govitecan |aOrAn=a |drugClass=Trop-2-directed antibody and topoisomerase inhibitor conjugate |indication='''Locally Advanced or Metastatic Breast Cancer''' TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one o..." current

12:5212:52, 8 May 2025 diff hist +26,864 N Opicapone Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=opicapone |aOrAn=a |drugClass=reversible and selectively peripheral COMT inhibition |indication=ONGENTYS is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes. |adverseReactions=The following clinically significant adverse reactions are discussed in more detail in other sections of the labeling: *Ca..." current
12:2812:28, 8 May 2025 diff hist +25,763 N Capmatinib Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=capmatinib |aOrAn=a |drugClass=kinase inhibitor targeting c-Met receptor tyrosine kinase |indicationType=treatment |indication=of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. |adverseReactions=The following clinically signific..." current
11:4011:40, 8 May 2025 diff hist −578 Selpercatinib No edit summary current
11:2111:21, 8 May 2025 diff hist +42,911 N Selpercatinib Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=selerpcatinib |aOrAn=a |drugClass=kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) |indication='''RET Fusion-Positive Non-Small Cell Lung Cancer''' RETEVMO® is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected b..."

11:4511:45, 4 May 2025 diff hist +11,699 N Fluoroestradiol f 18 Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=fluoroestradiol f 18 |drugClass=used to detect estrogen receptor-positive breast cancer lesions |indication=CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. |blackBoxWarningTitle='''TIT..." current
08:4808:48, 4 May 2025 diff hist +13,075 N Flortaucipir F18 Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=flortaucipir f-18 injection |drugClass=specifically bind to misfolded tau proteins in the brain |indicationType=treatment |indication=TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for..." current
08:2108:21, 4 May 2025 diff hist +25,323 N Inebilizumab-cdon Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=inebilizumab |aOrAn=a |drugClass=humanized monoclonal antibody against CD19 |indicationType=treatment |indication='''Neuromyelitis Optica Spectrum Disorder (NMOSD)''' UPLIZNA is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. '''Immunoglobulin G4-Related Disease (IgG4-RD)''' UPLI..." current

16:1916:19, 3 May 2025 diff hist +22,747 N Lurbinectedin Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=lurbinectedin |aOrAn=a |drugClass=inhibits transcription |indication=ZEPZELCA is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this in..." current
15:1215:12, 3 May 2025 diff hist +18,473 N Triheptanoin Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=triheptanoin |aOrAn=a |drugClass=source of heptanoate fatty acids |indicationType=treatment |indication=of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |fdaLIADAdu..." current
14:5314:53, 3 May 2025 diff hist +38,238 N Remimazolam Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=remimazolam |aOrAn=a |drugClass=activate of GABAa receptors |indication=BYFAVO® is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. |hasBlackBoxWarning=Yes |adverseReactions=*Neonatal Sedation and Withdrawal Syndrome |blackBoxWarningTitle='''PERSONNEL AND EQUIPMENT FOR MONITO..." current
13:3813:38, 3 May 2025 diff hist +26,283 N Fostemsavir Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=fostemsavir |aOrAn=a |drugClass=first-in-class HIV attachment inhibitor that works by attaching directly to HIV gp120 |indicationType=treatment |indication=of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety con..." current
13:1013:10, 3 May 2025 diff hist +22,146 N Decitabine and cedazuridine Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=decitabine and cedazuridine |drugClass=inhibits cytidine deaminase |indicationType=treatment |indication=INQOVI is indicated for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, ref..." current
12:4412:44, 3 May 2025 diff hist +15,559 N Abametapir Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=abametapir |aOrAn=a |drugClass=metalloproteinase inhibitor |indicationType=treatment |indication=of head lice infestation in patients 6 months of age and older. XEGLYZE should be used in the context of an overall lice management program: *Wash (with hot water) or dry-clean all recently worn clothing, hats, used bedding and towels *Wash personal care items such as combs, br..." current
09:2509:25, 3 May 2025 diff hist +18,983 N Tafasitamab-cxix Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=tafasitamab-cxix |aOrAn=a |drugClass=CD19-directed cytolytic monoclonal antibody |indication=MONJUVI, in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplan..." current

08:3208:32, 1 May 2025 diff hist +28,910 N Risdiplam Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=risdiplam |aOrAn=a |drugClass=enhancer of SMN2 gene transcription |indicationType=treatment |indication=spinal muscular atrophy (SMA) in pediatric and adult patients. |adverseReactions=Fever Diarrhea Rash Mouth and Aphtous Ulcers Arthralgia UTI |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition N..." current

19:1019:10, 30 April 2025 diff hist +49,230 N Oliceridine Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=oliceridine |aOrAn=an |drugClass=μ opioid agonist |indication=OLINVYK is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. |hasBlackBoxWarning=Yes |adverseReactions=The following adverse reactions are described, or described in greater detail, in other sections: *Addi..." current
18:3818:38, 30 April 2025 diff hist +16,108 N Viltolarsen Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=viltolarsen |aOrAn=a |drugClass=exon 53 of the dystrophin pre-mRNA |indicationType=treatment |indication=Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated..." current
18:2218:22, 30 April 2025 diff hist +21,434 N Satralizumab-mwge Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=satralizumab-mwge |aOrAn=a |drugClass=interleukin inhibitors |indication=ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. |adverseReactions=The following clinically significant adverse reactions are described elsewhere in the labeling: *Infections *Elevated Liver Enzym..." current
09:5509:55, 30 April 2025 diff hist −24 Clascoterone No edit summary current
09:5409:54, 30 April 2025 diff hist +13,347 N Clascoterone Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=Clascoterone |aOrAn=a |drugClass=androgen receptor antagonist |indicationType=treatment |indication=WINLEVI (clascoterone) cream is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Conditi..."
08:5308:53, 30 April 2025 diff hist +32,450 N Somapacitan-beco Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=somapacitan-beco |aOrAn=a |drugClass=binds to the growth hormone receptor and induces intracellular signalling to up-regulate insulin-like growth factor I (IGF-1) |indicationType=treatment |indication=SOGROYA is indicated for the: *Treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH). *Repla..." current
05:5605:56, 30 April 2025 diff hist +16,238 N Copper cu 64 dotatate injection Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=copper cu 64 dotatate injection |aOrAn=a |drugClass=somatostatin receptor-positive neuroendocrine tumors (NETs) |indicationType=diagnosis |indication=Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. |adverseReactions=The following clinically significant adverse r..." current

21:1321:13, 29 April 2025 diff hist +24,649 N Pralsetinib Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=pralsetinib |aOrAn=a |drugClass=RET receptor tyrosine kinase inhibitor |indicationType=treatment |indication=of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. |adverseReactions=*Interstitial Lung Disease/Pneumonitis *Hypertension *Hepatotoxicity *Hemorrhagic Events *Tumor Lysis Syndrome *Risk of Im..." current
20:5420:54, 29 April 2025 diff hist +13,818 N Atoltivimab, maftivimab, and odesivimab-ebgn Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=atoltivimab, maftivimab, and odesivimab-ebgn |aOrAn=a |drugClass=fixed-dose combination of three monoclonal antibodies |indicationType=treatment |indication=of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection |adverseReactions=Hypersensitivity Reactions Inc..." current
20:4220:42, 29 April 2025 diff hist +22,253 N Lonafarnib b Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=lonafarnib |aOrAn=a |drugClass=direct farnesyl transferase inhibitor |indication=ZOKINVY is indicated in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above: *To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS) *For the treatment of processing-deficient Progeroid Laminopathies with either: - Heterozygous LMNA mut..." current
19:5919:59, 29 April 2025 diff hist +14,552 N Lumasiran Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=lumsiran |aOrAn=an |drugClass=inhibits oxalate synthesis |indicationType=treatment |indication=of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients |adverseReactions=*Injection site reaction *Abdominal pain* |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''<span style="color:#..." current
19:4519:45, 29 April 2025 diff hist +23,681 N Setmelanotide Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=setmelanotide |aOrAn=a |drugClass=melanocortin-4 receptor (MC4R) agonist |indication=IMCIVREE is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to: |adverseReactions=*'''Disturbance in Sexual Arousal''' *'''Depression and Suicidal Ideation''' *'''Hypersensitivity Reactions''' *'''Skin Pigme..." current

18:0218:02, 27 April 2025 diff hist +5 Naxitamab No edit summary current
18:0118:01, 27 April 2025 diff hist +25,571 N Naxitamab Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=naxitamab |aOrAn=a |drugClass=IgG1 monoclonal antibody directed against GD2 disialogangliosides |indicationType=treatment |indication=of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. |hasBlackBox..."
17:2517:25, 27 April 2025 diff hist +23,551 N Berotralstat Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=berotralstat |aOrAn=a |drugClass=plasma kallikrein inhibitor |indicationType=prophylaxis |indication=to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older. |adverseReactions=QT Prolongation |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:</..." current
17:0517:05, 27 April 2025 diff hist +15,403 N Tirbanibulin Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=tirbanibulin |aOrAn=a |drugClass=non-ATP competitive Src kinase inhibitor and tubulin polymerization inhibitor. |indicationType=treatment |indication=of actinic keratosis on the face or scalp |adverseReactions=*Application site pruritus *Application site paina |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''..." current
16:1416:14, 27 April 2025 diff hist +21,662 N Margetuximab Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=margetuximab |aOrAn=a |drugClass=HER2/neu receptor antagonist |indicationType=treatment |indication=of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease |hasBlackBoxWarning=Yes |adverseReactions='''Left Ventricular Dysfunction''' '''Embryo-Fetal Toxicity''' '''Infusio..." current
15:5415:54, 27 April 2025 diff hist +24,276 N Relugolix Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=relugolix |aOrAn=a |drugClass=gonadotropin-releasing hormone (GnRH) receptor antagonist |indicationType=treatment |indication=of adult patients with advanced prostate cancer. |adverseReactions=QT/QTc Interval Prolongation |blackBoxWarningTitle='''TITLE''' |blackBoxWarningBody=''Condition Name:'' (Content) |fdaL..." current
14:5614:56, 27 April 2025 diff hist +18,021 N Ansuvimab-zykl Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=Ebanga |aOrAn=a |drugClass=ebolavirus (EBOV) glycoprotein 1 (GP1)-directed recombinant, human Immunoglobulin G1 (IgG1) monoclonal antibody. |indicationType=treatment |indication=of infection caused by Orthoebolavirus zairense(formerly Zaire ebolavirus) in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection..." current
14:2114:21, 27 April 2025 diff hist +20,784 N Vibegron Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=Gemtesa |aOrAn=a |drugClass=selective beta-3 adrenergic receptor |indicationType=treatment |indication=of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benig..." current

11:5311:53, 10 April 2025 diff hist +14,877 N Givinostat Hydrochloride Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=givinostat |aOrAn=an |drugClass=inhibits class I and class II histone deacetylases (HDACs) and several pro-inflammatory cytokines |indicationType=treatment |indication=of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older. |adverseReactions=*Hematological Changes *Increased Triglycerides *Gastrointestinal Disturbances *QTc Prolongation |blackBoxWarningTitle='..." current
10:3310:33, 10 April 2025 diff hist +18,496 N Sotatercept-csrk Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName= Alara Ece Dagsali, M.D. |aOrAn=an |drugClass=activin signalling inhibitor |indicationType=treatment |indication=of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events. |adverseReactions=*Erythrocytosis *Severe Thr..." current
06:0306:03, 10 April 2025 diff hist +16,208 N Nogapendekin alfa inbakicept-pmln Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=nogapendekin alfa inbakicept-pmln |aOrAn=an |drugClass=interleukin-15 (IL-15) receptor agonist |indicationType=treatment |indication=of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. |adverseReactions=The most common (≥15%) adverse reactions, were increased creatinine, dysuria, hematuri..." current

10:2010:20, 20 March 2025 diff hist +19,544 N Vadadustat Created page with "{{DrugProjectFormSinglePage |authorTag= Alara Ece Dagsali, M.D. |genericName=vadadustat |indicationType=treatment |indication=VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. |hasBlackBoxWarning=Yes |adverseReactions=*VAFSEO increases the risk of thrombotic vascular events, including major adverse cardiovascular events (MACE) *Targeting a hemoglobin lev..." current
09:4509:45, 20 March 2025 diff hist +2 Meningitis No edit summary current
09:4409:44, 20 March 2025 diff hist +39 Meningitis No edit summary

User contributions for Alara E. Dagsali

28 September 2025

13 May 2025

12 May 2025

11 May 2025

10 May 2025

9 May 2025

8 May 2025

4 May 2025

3 May 2025

1 May 2025

30 April 2025

29 April 2025

27 April 2025

10 April 2025

20 March 2025

Navigation menu

Search